A Multicenter, Randomized, Double-Blind, Active (Oseltamivir)-Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Otherwise Healthy Pediatric Patients 1 to <12 Years of Age With Influenza-Like Symptoms
Phase of Trial: Phase III
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Baloxavir-marboxil (Primary) ; Oseltamivir
- Indications Influenza virus infections
- Focus Adverse reactions; Registrational
- Sponsors Genentech; Roche
- 28 Nov 2018 Status changed from not yet recruiting to recruiting.
- 25 Oct 2018 Planned initiation date changed from 16 Nov 2018 to 13 Dec 2018.
- 23 Aug 2018 New trial record